

CBE 2979: Standardized Transfusion Ratio for Dialysis Facilities

5.4.3 Distribution Across Measured Entities

5.4.3 [If risk/case-mix factors are addressed by any method (5.4.1)] Variable Distribution Across Measured Entities*

Provide descriptive statistics showing how the risk/case mix variables identified from the conceptual model are distributed across the measured entities. Indicate which factors were tested in the risk/case-mix adjustment model and which were tested for stratifying the measure, as applicable.

Covariate	N of Facilities	Mean	5 th	25 th	Median	75 th	95 th
Age: 18-24 years old	1,446	4.3	0.1	0.7	1.4	2.4	6.2
Age: 25-44 years old	7,275	9.4	2.1	5.2	8.2	11.8	18.9
Age: 45-59 years old	7,732	22.9	9.4	16.8	22.0	27.5	37.2
Age: 60-74 years old	7,805	43.8	29.2	38.1	43.3	48.6	58.7
Age: 75 or older	7,697	26.2	10.6	18.7	25.0	32.3	45.0
Form 2728 Cause of ESRD: Diabetes	7,781	45.5	23.9	36.7	44.8	53.3	69.0
Form 2728 Cause of ESRD: Missing	1,515	2.4	0.1	0.4	1.0	1.9	5.4
Duration_of_ESRD: < 6 months	7,621	5.5	1.8	3.5	4.9	6.5	10.4
Duration_of_ESRD : 6 months-1 year	7,695	10.0	3.8	6.7	9.2	12.0	18.0
Duration_of_ESRD: 1-2 years	7,752	17.3	7.6	12.7	16.4	20.5	28.5
Duration_of_ESRD: 2-3 years	7,692	14.3	6.5	10.8	13.8	17.0	23.0
Duration_of_ESRD: 3-5 years	7,714	20.6	10.1	16.2	20.0	24.2	31.8
Duration_of_ESRD: 5+ years	7,796	35.0	15.0	26.5	34.3	42.3	54.9
Patient in a Nursing Home <90 days in last 365 days	7,430	9.9	2.0	5.7	8.9	12.6	20.4

Covariate	N of Facilities	Mean	5th	25th	Median	75th	95th
Patient in a Nursing Home 90 days or more in last 365 days	6,599	7.0	0.7	2.8	4.9	8.2	16.8
Incident BMI: underweight	5,773	3.6	0.4	1.7	2.8	4.5	8.3
Incident BMI: overweight	7,768	27.8	15.2	22.6	27.2	32.0	40.4
Incident BMI: obese	7,834	46.6	28.3	39.5	46.5	53.1	64.1
Incident Comorbidity: Atherosclerotic heart disease	7,068	10.7	1.2	4.3	8.2	14.3	28.1
Incident Comorbidity: Other cardiac disease	7,602	16.8	3.9	9.4	14.7	21.8	36.7
Incident Comorbidity: Congestive heart failure	7,699	23.0	8.5	16.0	21.8	28.3	40.5
Incident Comorbidity: Inability to ambulate	6,129	5.0	0.5	2.0	3.7	6.4	13.2
Incident Comorbidity: Chronic obstructive pulmonary disease	6,889	7.0	1.0	3.1	5.6	9.4	17.2
Incident Comorbidity: Inability to transfer	4,321	3.3	0.2	1.2	2.3	3.9	8.7
Incident Comorbidity: Malignant neoplasm, cancer	6,763	6.3	0.9	2.9	5.2	8.4	15.1
Incident Comorbidity: Diabetes (all types excluding cause of ESRD)	7,642	16.7	4.8	10.1	15.0	21.5	33.7
Incident Comorbidity: Peripheral vascular disease	6,907	7.7	1.0	3.4	5.9	9.5	19.2
Incident Comorbidity: Cerebrovascular disease, CVA, TIA	7,212	8.1	1.6	4.4	7.2	10.4	16.8
Incident Comorbidity: Tobacco use (current smoker)	6,807	7.3	0.9	3.1	5.9	9.7	17.5
Incident Comorbidity: Alcohol dependence	3,810	2.6	0.3	1.1	2.0	3.3	6.7

Covariate	N of Facilities	Mean	5th	25th	Median	75th	95th
Incident Comorbidity: Drug dependence	3,526	2.6	0.2	1.0	2.0	3.2	6.7
Incident Comorbidity: At least one of the incident comorbidities listed	7,856	76.1	58.0	70.4	76.8	82.7	92.2
Incident Comorbidity: No Medical Evidence (CMS-2728) Form	1,418	2.4	0.1	0.3	0.9	1.8	5.5
Days 1-30 after the first COVID-19 diagnosis	6,920	0.6	0.1	0.3	0.5	0.8	1.3
Days 31-60 after the first COVID-19 diagnosis	6,835	0.7	0.2	0.4	0.6	0.8	1.4
> 60 days after the first COVID-19 diagnosis	7,791	33.1	16.9	26.2	32.1	38.3	50.8
Medicare Advantage coverage	7,815	54.1	24.3	43.7	54.7	64.9	79.9
Prevalent Comorbidity*: Carcinoma in situ	2,729	1.9	0.1	0.6	1.4	2.3	4.5
Prevalent Comorbidity*: Coagulation disorders (not from dialysis claims)	7,037	6.2	0.7	2.7	4.8	8.0	15.1
Prevalent Comorbidity*: Head and neck cancer	1,731	1.6	0.1	0.5	1.1	2.0	4.1
Prevalent Comorbidity*: Hemolytic and aplastic anemia	7,089	5.7	0.7	2.7	4.6	6.9	12.1
Prevalent Comorbidity*: Leukemia	3,140	1.9	0.1	0.7	1.4	2.4	5.0
Prevalent Comorbidity*: Lymphoma	3,352	1.9	0.1	0.7	1.5	2.5	4.9
Prevalent Comorbidity*: Metastatic cancer	5,352	2.4	0.2	0.9	1.9	3.2	6.3
Prevalent Comorbidity*: Multiple myeloma, myelodysplastic syndrome and Myelofibrosis	6,425	3.9	0.4	1.8	3.2	5.0	9.4
Prevalent Comorbidity*: Other cancers (connective tissue, skin, and others)	2,743	1.6	0.1	0.5	1.2	2.1	4.1

Covariate	N of Facilities	Mean	5th	25th	Median	75th	95th
Prevalent Comorbidity*: Sickle cell anemia	1,344	1.7	0.1	0.6	1.3	2.1	4.1
Prevalent Comorbidity*: Solid organ cancer (breast, prostate, lung, digestive tract and others)	7,572	11.0	3.2	7.1	10.1	13.6	20.9
Prevalent Comorbidity*: Gastrointestinal (GI) bleeding	7,657	14.3	5.3	10.1	13.4	17.2	24.9

*Prevalent Comorbidities are indicators of comorbidities (claim sources: Part A/B/C) in the past 365 days from the beginning of each patient period at risk.